Information Provided By: 
Fly News Breaks for July 3, 2017
RHHBY, PTCT
Jul 3, 2017 | 05:40 EDT
After attending the Cure SMA Conference this weekend, Citi analyst Joel Beatty says favorable early clinical spinal muscular atrophy data presented by Roche (RHHBY) was suggestive that RG7916 will advance into the pivotal portion of its trials in the second half of 2017. This would trigger a $20M milestone from Roche to PTC Therapeutics (PTCT), Beatty tells investors in a research note. The analyst sees the data as de-risking and keeps a Buy rating on PTC shares.
News For PTCT;RHHBY From the Last 2 Days
PTCT
Apr 25, 2024 | 16:09 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
Reports Q1 revenue $210M, consensus $169.7M. "We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter," said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. "We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin."
RHHBY
Apr 25, 2024 | 11:44 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
